Co-founded by Stanford researchers, IgGenix is working on therapies that address severe allergies.

IgGenix, a US-based developer of an antibody-based approach to food allergies based on research at Stanford University, has raised $25m in an oversubscribed series A1 round co-led by Khosla Ventures and Matthias Westman. Alexandria Venture Investments, the venture capital unit of life sciences real estate investment trust Alexandria Real Estate Equities, also took part in…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.